Phase II trial of Survivin-responsive conditionally replicating adenovirus (Surv.m-CRA-1) by repeated local administration in patients with advanced primary malignant bone tumor. - SURV-B-study
100 Clinical Results associated with Surv BioPharma, Inc.
0 Patents (Medical) associated with Surv BioPharma, Inc.
100 Deals associated with Surv BioPharma, Inc.
100 Translational Medicine associated with Surv BioPharma, Inc.